Skip to content
  • Pipeline
    • Pipeline overview
    • Clinical development
    • Drug delivery technology
  • News
  • About us
    • Team
    • Advisory Board
    • Board of Directors
  • Contact
  • Pipeline
    • Go back
    • Pipeline overview
    • Clinical development
    • Drug delivery technology
  • News
  • About us
    • Go back
    • Team
    • Advisory Board
    • Board of Directors
  • Contact

Uncategorized

Lundbeck and Contera Pharma

Posted on 20. October 2025

CP-012: Positive topline results in Phase 1b trial

Posted on 17. September 2025

Last patient dosed in Phase 1b trial of CP-012

Posted on 28. August 2025

CP-102: CP0014753 is ready for IND-enabling studies

Posted on 14. March 2025

Contera Pharma Welcomes New Board Members to Drive Strategic Growth

Posted on 3. December 2024

CP-012: First patient dosed in Phase 1b trial

Posted on 28. November 2024

Contera Pharma A/S closes Korean office and consolidates all activities in Denmark – 2nd announcement

Posted on 18. October 2024

Contera Pharma A/S closes Korean office and consolidates all activities in Denmark

Posted on 23. September 2024

Contera Pharma strengthens its leadership team

Posted on 6. September 2024

JM-010: Topline results from Phase IIb clinical trial ASTORIA

Posted on 21. May 2024

Posts pagination

Previous 1 2 … 4 Next

Contera Pharma ApS

Venlighedsvej 4

2970 Hørsholm

Denmark

Thomas Sager, CEO
info@conterapharma.com

  • Pipeline
  • News
  • About us
  • Contact
2026 Contera Pharma

Cookie & privacy policy

Whistleblower